» Articles » PMID: 14654368

Cardiac Troponin T Mutation R141W Found in Dilated Cardiomyopathy Stabilizes the Troponin T-tropomyosin Interaction and Causes a Ca2+ Desensitization

Overview
Date 2003 Dec 5
PMID 14654368
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

A missense mutation R141W in the strong tropomyosin-binding region of cardiac troponin T (cTnT) has recently been reported to cause dilated cardiomyopathy (DCM), following the first report of a DCM-causing deletion mutation DeltaK210. To clarify the molecular mechanism for the pathogenesis of DCM caused by this novel mutation in cTnT gene, functional analyses were made on the recombinant human cTnT mutant proteins. Exchanging human wild-type and mutant cTnTs into rabbit skinned cardiac muscle fibers revealed that R141W mutation resulted in a decrease in the Ca(2+) sensitivity of force generation, as in the case of DeltaK210 mutation lying outside the strong tropomyosin-binding region. In contrast, a missense mutation R94L in the vicinity of the strong tropomyosin-binding region associated with hypertrophic cardiomyopathy (HCM) resulted in an increase in the Ca(2+) sensitivity of force generation, as in the case of the other HCM-causing mutations in cTnT reported previously. An assay using a quartz-crystal microbalance (a very sensitive mass-measuring device) revealed that R141W mutation increased the affinity of cTnT for alpha-tropomyosin by approximately three times, whereas an HCM-causing mutation DeltaE160 in the strong tropomyosin-binding region, as well as DeltaK210 and R94L mutations, had no effects on the interaction between cTnT and alpha-tropomyosin. Since cTnT has an important role in structurally integrating cardiac troponin I (cTnI) into the thin filaments via its two-way interactions with cTnI and tropomyosin, the present results suggest that R141W mutation in the strong tropomyosin-binding region in cTnT strengthens the integrity of cTnI in the thin filament by stabilizing the interaction between cTnT and tropomyosin, which might allow cTnI to inhibit the thin filament more effectively, leading to a Ca(2+) desensitization.

Citing Articles

Focus on cardiac troponin complex: From gene expression to cardiomyopathy.

Ragusa R, Caselli C Genes Dis. 2024; 11(6):101263.

PMID: 39211905 PMC: 11357864. DOI: 10.1016/j.gendis.2024.101263.


Structural dynamics of the intrinsically disordered linker region of cardiac troponin T.

Cubuk J, Greenberg L, Greenberg A, Emenecker R, Stuchell-Brereton M, Holehouse A bioRxiv. 2024; .

PMID: 38853835 PMC: 11160775. DOI: 10.1101/2024.05.30.596451.


Harnessing molecular mechanism for precision medicine in dilated cardiomyopathy caused by a mutation in troponin T.

Greenberg L, Stump W, Lin Z, Bredemeyer A, Blackwell T, Han X bioRxiv. 2024; .

PMID: 38645235 PMC: 11030379. DOI: 10.1101/2024.04.05.588306.


Cas13b-mediated RNA targeted therapy alleviates genetic dilated cardiomyopathy in mice.

Li J, Xuan H, Kuang X, Li Y, Lian H, Yu N Cell Biosci. 2024; 14(1):4.

PMID: 38178244 PMC: 10768345. DOI: 10.1186/s13578-023-01143-y.


Prognostic implications of troponin T variations in inherited cardiomyopathies using systems biology.

Shakur R, Ochoa J, Robinson A, Niroula A, Chandran A, Rahman T NPJ Genom Med. 2021; 6(1):47.

PMID: 34127679 PMC: 8203786. DOI: 10.1038/s41525-021-00204-w.